AbbVie Q1 2026 Revenue Hits $15B, Beats Estimates, Raises EPS Guidance
AbbVie (ABBV) reported Q1 2026 revenue of $15.002 billion, beating consensus by $284 million. The company also raised its full-year adjusted EPS guidance to a range of $14.08 to $14.28, reinforcing investor confidence in its growth trajectory.
Key Numbers
AbbVie (NYSE:ABBV) reported first-quarter 2026 results, posting revenue of $15.002 billion, exceeding analyst expectations by $284 million. The company also raised its full-year adjusted EPS guidance to $14.08-$14.28, boosting the stock which offers a dividend yield of nearly 3%.
Key Financial Results
| Metric | Q1 2026 | Consensus | Difference |
|---|---|---|---|
| Revenue | $15.002B | $14.718B | +$284M |
| Adjusted EPS | TBA | TBA | - |
| FY2026 Adj. EPS Guidance | $14.08 - $14.28 | Previously lower | - |
Highlights from the Release
Management attributed the strong quarter to successful portfolio diversification, particularly in oncology and immunology. Key products Skyrizi and Rinvoq continue to show robust growth.
Guidance
AbbVie raised its full-year adjusted EPS guidance to $14.08-$14.28, up from prior levels, reflecting confidence in sustained operational momentum.
Stock Impact
With a dividend yield of nearly 3%, ABBV remains attractive for income investors. The beat and raised guidance help alleviate bearish concerns about the Humira patent cliff.
What This Means for Investors
The Q1 results demonstrate AbbVie's ability to offset Humira revenue declines with new product growth. The guidance raise signals management confidence, potentially supporting the stock long-term.
Frequently Asked Questions
Found this useful? Share it